A new class of weight-loss drug just took a major step toward approval for use. In a phase 3 clinical trial, the medication retatrutide helped control blood sugar levels in participants with type 2 ...

You’ve heard of the popular glucagon-like peptide-1 (GLP-1) receptor agonist drug semaglutide (Ozempic, Wegovy) and GLP-1/GIP drug tirzepatide (Mounjaro, Zepbound). Now there’s a new kid on the weight ...

Retatrutide weight loss drug trials recorded 28.3% average body weight loss, outpacing surgery and all existing GLP-1 ...

Retatrutide met primary and key secondary endpoints in a 2339-participant, randomized, double-blind, placebo-controlled phase 3 trial, demonstrating clinically meaningful weight reduction across 4, 9, ...

iPercent body weight reduction with retatrutide 4 mg was a key secondary endpoint. iiThe extension period enrolled 532 participants with BMI ≥35 at baseline who had completed the main 80-week study ...

Please provide your email address to receive an email when new articles are posted on . Retatrutide was tied to weight loss ranging from 19% with a 4 mg dose to 28.3% with a 12 mg dose at 80 weeks. Of ...

An experimental drug nicknamed "Reta" produced greater weight loss than any GLP-1 currently on the market — but it may not be suitable for everyone. The experimental drug retatrutide helped adults ...